These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21923688)

  • 1. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
    Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
    Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
    Lee BH; Kim N; Hwang TJ; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Helicobacter; 2010 Feb; 15(1):38-45. PubMed ID: 20302588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
    Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
    Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
    Wang Z; Wu S
    Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
    Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N
    Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
    Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
    Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
    Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection.
    Minakari M; Davarpanah Jazi AH; Shavakhi A; Moghareabed N; Fatahi F
    Helicobacter; 2010 Apr; 15(2):154-9. PubMed ID: 20402818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
    Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.